Celgene Corporation (NASDAQ:CELG) issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04, MarketWatch Earnings reports. The firm had revenue of $3.29 billion for the quarter, compared to the consensus estimate of $3.42 billion. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. Celgene Corporation’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period last year, the firm posted $1.58 EPS. Celgene Corporation updated its FY17 guidance to $7.30-7.35 EPS.
Celgene Corporation (CELG) traded down $0.12 during midday trading on Friday, reaching $102.34. 6,473,500 shares of the company’s stock were exchanged, compared to its average volume of 4,674,886. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. The firm has a market capitalization of $80,668.49, a PE ratio of 16.01, a PEG ratio of 0.79 and a beta of 1.79. Celgene Corporation has a 1 year low of $94.55 and a 1 year high of $147.17.
In other Celgene Corporation news, Director Gilla Kaplan sold 9,250 shares of Celgene Corporation stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the completion of the sale, the director now directly owns 85,551 shares in the company, valued at $12,110,599.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Terrie Curran sold 1,727 shares of Celgene Corporation stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the sale, the insider now owns 3,925 shares of the company’s stock, valued at $564,768.25. The disclosure for this sale can be found here. Insiders sold 20,227 shares of company stock valued at $2,843,956 over the last quarter. Corporate insiders own 0.95% of the company’s stock.
Several institutional investors have recently modified their holdings of CELG. Ark Investment Management LLC lifted its stake in shares of Celgene Corporation by 78.7% in the second quarter. Ark Investment Management LLC now owns 1,599 shares of the biopharmaceutical company’s stock worth $208,000 after buying an additional 704 shares during the last quarter. Westwood Holdings Group Inc. acquired a new stake in shares of Celgene Corporation in the second quarter worth $236,000. 1st Global Advisors Inc. lifted its stake in shares of Celgene Corporation by 29.0% in the second quarter. 1st Global Advisors Inc. now owns 2,564 shares of the biopharmaceutical company’s stock worth $333,000 after buying an additional 577 shares during the last quarter. Keel Point LLC lifted its stake in shares of Celgene Corporation by 4.5% in the second quarter. Keel Point LLC now owns 3,244 shares of the biopharmaceutical company’s stock worth $421,000 after buying an additional 141 shares during the last quarter. Finally, Krilogy Financial LLC lifted its stake in shares of Celgene Corporation by 65.0% in the second quarter. Krilogy Financial LLC now owns 3,540 shares of the biopharmaceutical company’s stock worth $460,000 after buying an additional 1,395 shares during the last quarter. Institutional investors and hedge funds own 78.92% of the company’s stock.
Several brokerages recently weighed in on CELG. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $175.00 price objective on shares of Celgene Corporation in a research report on Wednesday, August 9th. Vetr upgraded shares of Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 price objective on the stock in a research report on Wednesday, August 16th. BMO Capital Markets cut their price objective on shares of Celgene Corporation from $163.00 to $148.00 and set an “outperform” rating on the stock in a research report on Friday, October 27th. Cantor Fitzgerald reiterated a “buy” rating and issued a $162.00 price objective on shares of Celgene Corporation in a research report on Tuesday, September 26th. Finally, SunTrust Banks, Inc. reiterated a “buy” rating and issued a $150.00 price objective on shares of Celgene Corporation in a research report on Friday, July 14th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have issued a buy rating and two have assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $139.64.
TRADEMARK VIOLATION WARNING: This piece was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2017/11/11/celgene-corporation-celg-announces-earnings-results.html.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.